Withdrawal symptoms happen in infants born to moms who obtain barbiturates through the last trimester of pregnancy
fentanyl transdermal and pentobarbital the two improve sedation. Stay clear of or Use Alternate Drug. Restrict use to people for whom option treatment solutions are inadequate
pentobarbital will minimize the level or outcome of conjugated estrogens by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
fentanyl intranasal and pentobarbital both equally increase sedation. Prevent or Use Alternate Drug. Restrict use to clients for whom option procedure choices are insufficient
pentobarbital will lessen the extent or impact of conivaptan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will lower the level or result of stiripentol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. If struggling to prevent coadministration of stiripentol with robust CYP3A4 inducers, increase stiripentol dose.
With therapeutic doses of TCAs, barbiturates enhance metabolism and reduce blood concentrations of TCAs.
pentobarbital will decrease the extent or effect of fostemsavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will lower the extent or effect of estradiol vaginal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will lessen the extent or impact of nitrendipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unidentified.
By clicking check here ship, you admit that you've permission to e-mail the receiver with this details.
pentobarbital will reduce the extent or impact of vinblastine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Not known.
Keep track of Intently (one)pentobarbital will lessen the level or outcome of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Loss of, or lessened response to tofacitinib may possibly occur when coadministered with powerful CYP3A4 inducers
Monoamine oxidase inhibitors (MAOI) may possibly inhibit barbiturate metabolism and prolong barbiturate effects; keep track of closely